Effectiveness of administration of Optix Forte in patients with primary open angle glaucoma
The aim of the present research is to study the effectiveness of administration of Optix Forte in patients with primary open angle glaucoma. Data were collected from 73 patients with primary open angle glaucoma of I and II stage, who are of a similar age, sex, IOP and having similar perimetry data. The patients of group 1 were treated with Optix Forte as part of the combined therapy in the recommended dose 2 capsules a day for 3 months. The patients of group 2 received only antihypertensive therapy during the research. In patients who were treated with Optix forte as part of the combined therapy of primary open angle glaucoma after 3 months of taking the drug there has been an increase in uncorrected visual acuity by 0.1±0.04 in the I stage of POAG and by 0.07±0.02 -in the II stage (p>0.05), which may be attributed to the effect of lutein and zeaxanthin that are components of the drug. In patients taking Optix Forte the parameters of overall photosensitivity of the retina and local defects during 3 months of the research remain stable. No negative trend was noted when comparing the data of laser polarimetry before and after three months of taking the drug. The positive effect of taking the drug Optix Forte was noted by the patients in 48.65% of cases, 45.95% of the patients did not notice changes in visual functions and 5.4% of the patients reported their subjective deterioration. Based on the results obtained, the use of the drug Optix Forte as part of the combined therapy in patients with open angle glaucoma proves to be justified and contributes to stabilization of functional parameters of the visual organ.